{"id":79672,"date":"2026-06-08T17:35:21","date_gmt":"2026-06-08T17:35:21","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/79672\/"},"modified":"2026-06-08T17:35:21","modified_gmt":"2026-06-08T17:35:21","slug":"roche-nurix-2-3b-licensing-agreement-for-bexobrutideg-btk-degrader-for-blood-cancers-news-and-statistics","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/79672\/","title":{"rendered":"Roche-Nurix $2.3B Licensing Agreement for Bexobrutideg: BTK Degrader for Blood Cancers &#8211; News and Statistics"},"content":{"rendered":"<p>\n\t\t\t\t\t\t\t\t\t\t\t\tJun 8, 2026\t\t\t\t\t<\/p>\n<p><a href=\"https:\/\/www.indexbox.io\/store\/branch\/biopharmaceuticals-biotechnology\/\" target=\"_blank\" rel=\"nofollow noopener\">Roche Holding has entered<\/a> into a licensing agreement with <a href=\"https:\/\/app.indexbox.io\/companies\/profile\/4734115\/\" target=\"_blank\" rel=\"noopener nofollow\">Nurix Therapeutics<\/a> for an experimental blood-cancer drug, with the deal valued at up to $2.3 billion. The agreement, announced on Monday, aims to strengthen Roche&#8217;s oncology pipeline and may extend into other therapeutic areas, according to the source.<\/p>\n<p>The Swiss pharmaceutical company will make an upfront cash payment of $700 million to Nurix. Additional payments are contingent on the drug, named bexobrutideg, achieving specific development, regulatory, and sales milestones.<\/p>\n<p>Bexobrutideg is scheduled to enter late-stage clinical trials for chronic lymphocytic leukemia this summer, Roche stated. Roche&#8217;s deputy chief medical officer, Stefan Frings, indicated in an interview that the primary focus is on B-cell malignancies, with chronic lymphocytic leukemia being the most significant area of interest.<\/p>\n<p>The company noted that the medicine may provide higher effectiveness and a better tolerability profile compared to existing leukemia therapies. Bexobrutideg is a BTK degrader, designed to eliminate the BTK enzyme from cells rather than merely blocking its activity, potentially overcoming resistance.<\/p>\n<p>Roche intends to explore whether the drug can be combined with other treatments for blood cancers and whether it could be effective in other conditions, such as multiple sclerosis and chronic spontaneous urticaria\u2014a form of chronic hives without a known cause. Frings commented that hematology represents a substantial and relatively low-risk opportunity, while the other potential applications are promising but carry higher uncertainty.<\/p>\n<p>Development costs will be split between the two companies, with Roche covering 60% and Nurix covering 40%. Profits and losses from commercialization in the United States will be shared equally, while Roche will handle commercialization in all other markets.<\/p>\n<p>\t\t1. INTRODUCTION<\/p>\n<p class=\"text-secondary fs-6\">Making Data-Driven Decisions to Grow Your Business<\/p>\n<p>\t\t\t\tREPORT DESCRIPTION<br \/>\n\t\t\t\tRESEARCH METHODOLOGY AND THE AI PLATFORM<br \/>\n\t\t\t\tDATA-DRIVEN DECISIONS FOR YOUR BUSINESS<br \/>\n\t\t\t\tGLOSSARY AND SPECIFIC TERMS<\/p>\n<p>\t\t2. EXECUTIVE SUMMARY<\/p>\n<p class=\"text-secondary fs-6\">A Quick Overview of Market Performance<\/p>\n<p>\t\t\t\tKEY FINDINGS<br \/>\n\t\t\t\tMARKET TRENDS <a class=\"px-2\" href=\"https:\/\/www.indexbox.io\/licenses\/\" target=\"_blank\" rel=\"nofollow noopener\">This Chapter is Available Only for the Professional Edition<\/a>PRO<\/p>\n<p>\t\t3. MARKET OVERVIEW<\/p>\n<p class=\"text-secondary fs-6\">Understanding the Current State of The Market and its Prospects<\/p>\n<p>\t\t\t\tMARKET SIZE: HISTORICAL DATA (2012\u20132025) AND FORECAST (2026\u20132035)<br \/>\n\t\t\t\tCONSUMPTION BY COUNTRY: HISTORICAL DATA (2012\u20132025) AND FORECAST (2026\u20132035)<br \/>\n\t\t\t\tMARKET FORECAST TO 2035<\/p>\n<p>\t\t4. MOST PROMISING PRODUCTS FOR DIVERSIFICATION<\/p>\n<p class=\"text-secondary fs-6\">Finding New Products to Diversify Your Business<\/p>\n<p>\t\t\t\tTOP PRODUCTS TO DIVERSIFY YOUR BUSINESS<br \/>\n\t\t\t\tBEST-SELLING PRODUCTS<br \/>\n\t\t\t\tMOST CONSUMED PRODUCTS<br \/>\n\t\t\t\tMOST TRADED PRODUCTS<br \/>\n\t\t\t\tMOST PROFITABLE PRODUCTS FOR EXPORT<\/p>\n<p>\t\t5. MOST PROMISING SUPPLYING COUNTRIES<\/p>\n<p class=\"text-secondary fs-6\">Choosing the Best Countries to Establish Your Sustainable Supply Chain<\/p>\n<p>\t\t\t\tTOP COUNTRIES TO SOURCE YOUR PRODUCT<br \/>\n\t\t\t\tTOP PRODUCING COUNTRIES<br \/>\n\t\t\t\tTOP EXPORTING COUNTRIES<br \/>\n\t\t\t\tLOW-COST EXPORTING COUNTRIES<\/p>\n<p>\t\t6. MOST PROMISING OVERSEAS MARKETS<\/p>\n<p class=\"text-secondary fs-6\">Choosing the Best Countries to Boost Your Export<\/p>\n<p>\t\t\t\tTOP OVERSEAS MARKETS FOR EXPORTING YOUR PRODUCT<br \/>\n\t\t\t\tTOP CONSUMING MARKETS<br \/>\n\t\t\t\tUNSATURATED MARKETS<br \/>\n\t\t\t\tTOP IMPORTING MARKETS<br \/>\n\t\t\t\tMOST PROFITABLE MARKETS<\/p>\n<p>\t\t7. PRODUCTION<\/p>\n<p class=\"text-secondary fs-6\">The Latest Trends and Insights into The Industry<\/p>\n<p>\t\t\t\tPRODUCTION VOLUME AND VALUE: HISTORICAL DATA (2012\u20132025) AND FORECAST (2026\u20132035)<br \/>\n\t\t\t\tPRODUCTION BY COUNTRY: HISTORICAL DATA (2012\u20132025) AND FORECAST (2026\u20132035)<\/p>\n<p>\t\t8. IMPORTS<\/p>\n<p class=\"text-secondary fs-6\">The Largest Import Supplying Countries<\/p>\n<p>\t\t\t\tIMPORTS: HISTORICAL DATA (2012\u20132025) AND FORECAST (2026\u20132035)<br \/>\n\t\t\t\tIMPORTS BY COUNTRY: HISTORICAL DATA (2012\u20132025) AND FORECAST (2026\u20132035)<br \/>\n\t\t\t\tIMPORT PRICES BY COUNTRY: HISTORICAL DATA (2012\u20132025) AND FORECAST (2026\u20132035)<\/p>\n<p>\t\t9. EXPORTS<\/p>\n<p class=\"text-secondary fs-6\">The Largest Destinations for Exports<\/p>\n<p>\t\t\t\tEXPORTS: HISTORICAL DATA (2012\u20132025) AND FORECAST (2026\u20132035)<br \/>\n\t\t\t\tEXPORTS BY COUNTRY: HISTORICAL DATA (2012\u20132025) AND FORECAST (2026\u20132035)<br \/>\n\t\t\t\tEXPORT PRICES BY COUNTRY: HISTORICAL DATA (2012\u20132025) AND FORECAST (2026\u20132035)<\/p>\n<p>\t\t10. PROFILES OF MAJOR PRODUCERS<\/p>\n<p class=\"text-secondary fs-6\">The Largest Producers on The Market and Their Profiles<\/p>\n<p>                        11. COUNTRY PROFILES<\/p>\n<p class=\"text-secondary fs-6\">The Largest Markets And Their Profiles<\/p>\n<p>                        <a class=\"pe-2 fs-5 mb-2\" target=\"_blank\" href=\"https:\/\/www.indexbox.io\/licenses\/\" rel=\"nofollow noopener\">This Chapter is Available Only for the Professional Edition<\/a><br \/>\n                        PRO<\/p>\n<p>11.1<\/p>\n<p>United States<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.2<\/p>\n<p>China<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.3<\/p>\n<p>Japan<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.4<\/p>\n<p>Germany<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.5<\/p>\n<p>United Kingdom<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.6<\/p>\n<p>France<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.7<\/p>\n<p>Brazil<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.8<\/p>\n<p>Italy<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.9<\/p>\n<p>Russian Federation<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.10<\/p>\n<p>India<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.11<\/p>\n<p>Canada<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.12<\/p>\n<p>Australia<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.13<\/p>\n<p>Republic of Korea<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.14<\/p>\n<p>Spain<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.15<\/p>\n<p>Mexico<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.16<\/p>\n<p>Indonesia<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.17<\/p>\n<p>Netherlands<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.18<\/p>\n<p>Turkey<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.19<\/p>\n<p>Saudi Arabia<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.20<\/p>\n<p>Switzerland<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.21<\/p>\n<p>Sweden<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.22<\/p>\n<p>Nigeria<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.23<\/p>\n<p>Poland<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.24<\/p>\n<p>Belgium<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.25<\/p>\n<p>Argentina<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.26<\/p>\n<p>Norway<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.27<\/p>\n<p>Austria<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.28<\/p>\n<p>Thailand<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.29<\/p>\n<p>United Arab Emirates<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.30<\/p>\n<p>Colombia<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.31<\/p>\n<p>Denmark<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.32<\/p>\n<p>South Africa<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.33<\/p>\n<p>Malaysia<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.34<\/p>\n<p>Israel<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.35<\/p>\n<p>Singapore<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.36<\/p>\n<p>Egypt<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.37<\/p>\n<p>Philippines<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.38<\/p>\n<p>Finland<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.39<\/p>\n<p>Chile<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.40<\/p>\n<p>Ireland<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.41<\/p>\n<p>Pakistan<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.42<\/p>\n<p>Greece<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.43<\/p>\n<p>Portugal<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.44<\/p>\n<p>Kazakhstan<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.45<\/p>\n<p>Algeria<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.46<\/p>\n<p>Czech Republic<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.47<\/p>\n<p>Qatar<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.48<\/p>\n<p>Peru<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.49<\/p>\n<p>Romania<\/p>\n<p>Market SizeProductionImportsExports<\/p>\n<p>11.50<\/p>\n<p>Vietnam<\/p>\n<p>Market SizeProductionImportsExports<br \/>\n\t\tLIST OF TABLES<\/p>\n<p>\t\t\t\tKey Findings In 2025<br \/>\n\t\t\t\tMarket Volume, In Physical Terms: Historical Data (2012\u20132025) and Forecast (2026\u20132035)<br \/>\n\t\t\t\tMarket Value: Historical Data (2012\u20132025) and Forecast (2026\u20132035)<br \/>\n\t\t\t\tPer Capita Consumption, by Country, 2022\u20132025<br \/>\n\t\t\t\tProduction, In Physical Terms, By Country: Historical Data (2012\u20132025) and Forecast (2026\u20132035)<br \/>\n\t\t\t\tImports, In Physical Terms, By Country: Historical Data (2012\u20132025) and Forecast (2026\u20132035)<br \/>\n\t\t\t\tImports, In Value Terms, By Country: Historical Data (2012\u20132025) and Forecast (2026\u20132035)<br \/>\n\t\t\t\tImport Prices, By Country: Historical Data (2012\u20132025) and Forecast (2026\u20132035)<br \/>\n\t\t\t\tExports, In Physical Terms, By Country: Historical Data (2012\u20132025) and Forecast (2026\u20132035)<br \/>\n\t\t\t\tExports, In Value Terms, By Country: Historical Data (2012\u20132025) and Forecast (2026\u20132035)<br \/>\n\t\t\t\tExport Prices, By Country: Historical Data (2012\u20132025) and Forecast (2026\u20132035)<\/p>\n<p>\t\tLIST OF FIGURES<\/p>\n<p>\t\t\t\tMarket Volume, In Physical Terms: Historical Data (2012\u20132025) and Forecast (2026\u20132035)<br \/>\n\t\t\t\tMarket Value: Historical Data (2012\u20132025) and Forecast (2026\u20132035)<br \/>\n\t\t\t\tConsumption, by Country, 2025<br \/>\n\t\t\t\tMarket Volume Forecast to 2035<br \/>\n\t\t\t\tMarket Value Forecast to 2035<br \/>\n\t\t\t\tMarket Size and Growth, By Product<br \/>\n\t\t\t\tAverage Per Capita Consumption, By Product<br \/>\n\t\t\t\tExports and Growth, By Product<br \/>\n\t\t\t\tExport Prices and Growth, By Product<br \/>\n\t\t\t\tProduction Volume and Growth<br \/>\n\t\t\t\tExports and Growth<br \/>\n\t\t\t\tExport Prices and Growth<br \/>\n\t\t\t\tMarket Size and Growth<br \/>\n\t\t\t\tPer Capita Consumption<br \/>\n\t\t\t\tImports and Growth<br \/>\n\t\t\t\tImport Prices<br \/>\n\t\t\t\tProduction, In Physical Terms: Historical Data (2012\u20132025) and Forecast (2026\u20132035)<br \/>\n\t\t\t\tProduction, In Value Terms: Historical Data (2012\u20132025) and Forecast (2026\u20132035)<br \/>\n\t\t\t\tProduction, by Country, 2025<br \/>\n\t\t\t\tProduction, In Physical Terms, by Country: Historical Data (2012\u20132025) and Forecast (2026\u20132035)<br \/>\n\t\t\t\tImports, In Physical Terms: Historical Data (2012\u20132025) and Forecast (2026\u20132035)<br \/>\n\t\t\t\tImports, In Value Terms: Historical Data (2012\u20132025) and Forecast (2026\u20132035)<br \/>\n\t\t\t\tImports, In Physical Terms, By Country, 2025<br \/>\n\t\t\t\tImports, In Physical Terms, By Country: Historical Data (2012\u20132025) and Forecast (2026\u20132035)<br \/>\n\t\t\t\tImports, In Value Terms, By Country: Historical Data (2012\u20132025) and Forecast (2026\u20132035)<br \/>\n\t\t\t\tImport Prices, By Country: Historical Data (2012\u20132025) and Forecast (2026\u20132035)<br \/>\n\t\t\t\tExports, In Physical Terms: Historical Data (2012\u20132025) and Forecast (2026\u20132035)<br \/>\n\t\t\t\tExports, In Value Terms: Historical Data (2012\u20132025) and Forecast (2026\u20132035)<br \/>\n\t\t\t\tExports, In Physical Terms, By Country, 2025<br \/>\n\t\t\t\tExports, In Physical Terms, By Country: Historical Data (2012\u20132025) and Forecast (2026\u20132035)<br \/>\n\t\t\t\tExports, In Value Terms, By Country: Historical Data (2012\u20132025) and Forecast (2026\u20132035)<br \/>\n\t\t\t\tExport Prices, By Country: Historical Data (2012\u20132025) and Forecast (2026\u20132035)<\/p>\n","protected":false},"excerpt":{"rendered":"Jun 8, 2026 Roche Holding has entered into a licensing agreement with Nurix Therapeutics for an experimental blood-cancer&hellip;\n","protected":false},"author":2,"featured_media":79673,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[41368,41223,41251,41370,41371,41362,41221,41369,265,134,994],"class_list":["post-79672","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-b-cell-malignancies","tag-bexobrutideg","tag-btk-degrader","tag-cbl-b","tag-chemotherapy","tag-chronic-lymphocytic-leukemia","tag-nurix-therapeutics","tag-nx-2127","tag-oncology","tag-roche","tag-roche-holding"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116715698502126681","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/79672","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=79672"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/79672\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/79673"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=79672"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=79672"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=79672"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}